A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Unresectable Solid Tumor
Metastatic Solid Tumor
Colorectal Adenocarcinoma
Pancreatic Adenocarcinoma
Lung Cancer
Ovarian Cancer
Breast Cancer
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Bladder Cancer

Interventions

DRUG: CLSP-1025

Sponsor

Clasp Therapeutics, Inc.